Remote assessment of disease and relapse – Alzheimer’s disease


Start Date
End Date
IMI2 - Call 12
Grant agreement number

Type of Action: 
RIA (Research and Innovation Action)

IMI Funding
4 999 757
EFPIA in kind
2 327 402
Associated Partners
223 132
89 854
Total Cost
7 640 145


People in the earliest stages of Alzheimer’s disease experience declining cognitive and functional abilities, making it harder for them to remember things and places, carry out simple calculations, use a phone/computer, drive, and adhere to medications. The goal of the RADAR-AD platform is to develop a digital platform that would draw on smartphone, wearable and home-based digital technologies to track subtle changes in the cognitive and functional abilities of people with Alzheimer’s disease. The project will adapt the existing RADAR-CNS project’s platform for Alzheimer’s disease. Among other things, the team will have to take account of the fact that many people with Alzheimer’s disease are older and so may be less familiar with technology, while their condition may make it more difficult for them to learn to handle technological devices. People with Alzheimer’s disease will be fundamentally involved in the design and development of the project so that the systems put in place are acceptable and appropriate for them. The platform will be tested in a clinical study with people with different stages of Alzheimer’s disease. Ultimately, the project results will make it easier to assess how well new dementia treatments work.

Participants Show participants on map

EFPIA companies
  • Eli Lilly and Company Limited, Basingstoke, United Kingdom
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Novartis Pharma AG, Basel, Switzerland
  • Takeda Development Centre Europe LTD., London, United Kingdom
Universities, research organisations, public bodies, non-profit groups
  • Agentschap College Ter Beoordeling Van Geneesmiddelen, Utrecht, Netherlands
  • Ethniko Kentro Erevnas Kai Technologikis Anaptyxis, Thermi Thessaloniki, Greece
  • Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany
  • Karolinska Institutet, Stockholm, Sweden
  • King'S College London, London, United Kingdom
  • Stichting Vumc, Amsterdam, Netherlands
  • University of Oxford, Oxford, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Altoida AG, Luzern, Switzerland
  • Stichting Lygature, Utrecht, Netherlands
  • The Hyve BV, Utrecht, Netherlands
Patient organisations
  • Alzheimer Europe, Luxembourg, Luxembourg
Associated partners
  • Software AG, Darmstadt, Germany


Project coordinator